NewAmsterdam Pharma Receives Marketing Authorization From European Commission For Ubeslo, Evlarco To Treat Primary Hypercholesterolaemia

NewAmsterdam Pharma Company N.V. has received marketing authorization from the European Commission for its products Ubeslo® and Evlarco®, aimed at treating primary hypercholesterolaemia. Ubeslo® is a 10 mg monotherapy of obicetrapib, while Evlarco® is a fixed-dose combination of 10 mg obicetrapib and 10 mg ezetimibe. This marks the first regulatory approval of obicetrapib globally, highlighting a significant milestone for the company and its partner Menarini Group.